Literature DB >> 3342667

Usefulness of tissue polypeptide antigen in staging, monitoring, and prognosis of lung cancer.

G Buccheri1, D Ferrigno.   

Abstract

A study of tissue polypeptide antigen (TPA) serum levels was conducted in patients with various cell types of bronchial carcinoma. A total of 548 assays (226 pretreatment) were evaluated. In all, the sensitivity of the test at diagnosis was 61 percent. It varied considerably in relation to the extent and site of disease. Individual pretreatment values of TPA correlated significantly with the stage of disease. Similarly, posttreatment TPA values related to disease evolution. In small cell carcinoma, eight of the 29 meaningful changes in follow-up levels of TPA preceded clinical recognition of disease status variations. Raised pretreatment values of TPA were significantly associated with a shortened survival. These results indicate that TPA may contribute to staging, monitoring, and prognosis of lung cancer.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3342667     DOI: 10.1378/chest.93.3.565

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  4 in total

1.  Relationship between TA01 and TA02 polypeptides associated with lung adenocarcinoma and histocytological features.

Authors:  T Hirano; K Fujioka; B Franzèn; K Okuzawa; K Uryu; H Shibanuma; K Numata; C Konaka; Y Ebihara; M Takahashi; H Kato; G Auer
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

2.  Lung tumour markers in oncology practice: a study of TPA and CA125.

Authors:  G Buccheri; D Ferrigno
Journal:  Br J Cancer       Date:  2002-11-04       Impact factor: 7.640

Review 3.  [Clinical utility of serum tumor markers in lung cancer].

Authors:  Xiao Zhao; Mengzhao Wang
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2011-03

4.  CYFRA 21-1 is a prognostic determinant in non-small-cell lung cancer: results of a meta-analysis in 2063 patients.

Authors:  J-L Pujol; O Molinier; W Ebert; J-P Daurès; F Barlesi; G Buccheri; M Paesmans; E Quoix; D Moro-Sibilot; M Szturmowicz; J-M Bréchot; T Muley; J Grenier
Journal:  Br J Cancer       Date:  2004-06-01       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.